Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023


Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's business and research and development pipeline.

Conference Call and Webcast Information

A live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To join by phone, participants can register for the call here. It is recommended that participants register one day in advance or at a minimum of 30 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta's website for approximately 30 days following the event.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 05:28
Sensible Money (sensiblemoney.com), a leader in helping clients transition out of the workforce into a financially secure retirement, is pleased to announce the firm has been named by InvestmentNews to its list of Best Places to Work for Financial...

at 05:22
On March 1st, the global accelerator programme initiated by Zetrix, a layer-1 blockchain platform utilising Delegated Proof of Stake (DPoS) mechanism, in collaboration with Web3.0 startup hub Web3Labs, is officially open for registration. The...

at 05:00
Power Knot Ocean, the market leader for onsite organic waste management solutions in the marine environment, announced today the successful deployment of 26 of its machines aboard Princess Cruises' latest luxury cruise ship, the Sun Princess. The...

at 05:00
Bybit, one of the world's top three crypto exchanges by volume, now unveils March's Fiat Cashback Splash for both fresh and seasoned users who make fiat deposits....

at 05:00
ezW2Correction software from Halfpricesoft.com, offers support for employers and tax professionals to seamlessly process and file W2C and W3C correction forms. With one 2023 version, clients can process unlimited corrections from years 2014-2023....

at 05:00
The federal government will make a housing announcement in Bathurst. Media are invited to join the Honourable Sean Fraser, Minister...



News published on and distributed by: